Weekly Digest – February 2026 Weekly Digest – February 2026 04 February 2026: DS3790 enters clinical development as first DXd ADC in hematology from industry-leading ADC portfolio of Daiichi Sankyo Daiichi Sankyo has reached a key milestone in hematologic oncology, […]
Weekly Digest – February 2026 Weekly Digest – February 2026 02 February 2026: AdvanCell announces collaboration and exclusive licensing agreement with 48Hour discovery to develop a novel peptide-based lead-212 radiotherapeutic for a gastrointestinal cancer with significant medical need AdvanCell has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 27 January 2026: Henlius receives an IND approval for Its PD-L1-targeting ADC HLX43 in combination with anti-PD-1 mAb Serplulimab and novel anti-EGFR mAb HLX07 Shanghai Henlius Biotech has secured regulatory […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 January 2026: MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study for relapsed or refractory Diffuse Large B-cell Lymphoma Tanabe Pharma announced a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: China Isotope & Radiation Corporation signs commercial deal for Pluvicto, China’s first PSMA radioligand therapy China Isotope & Radiation Corporation disclosed that its subsidiary, Atom High-Tech, has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 January 2026: HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics HealZen Therapeutics has taken a major step onto the global stage, announcing a strategic collaboration with a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 January 2026: Fortitude Biomedicines launches with $13M in financing to advance novel antibody-based therapies for treatment of autoimmune diseases and cancer Fortitude Biomedicines has officially launched with $13 million […]
Weekly Digest – January 2026 Weekly Digest – January 2026 27 January 2026: StarkAge Therapeutics announces research collaboration with Gustave Roussy to advance senolytic therapies in digestive cancers StarkAge Therapeutics has entered a strategic research collaboration with Gustave Roussy, Europe’s […]
Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer ENHERTU (trastuzumab deruxtecan) has been approved in China for the second-line treatment of adults with […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy Daiichi Sankyo Korea and AstraZeneca Korea announced that Enhertu (trastuzumab deruxtecan) has received approval from Korea’s Ministry of Food […]
